Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study

References

• De CaterinaRHustedSWallentinLAnticoagulants in heart disease: current status and perspectivesEur Heart J200728788091317426080
   PubMed Web of Science ®Google Scholar
• WeitzDSWeitzJIUpdate on heparin: what do we need to know?J Thromb Thrombolysis201029219920719882363
   PubMed Web of Science ®Google Scholar
• MotlekarNAYouanBBThe quest for non-invasive delivery of bioactive macromolecules: a focus on heparinsJ Control Release200611329110116777255
   PubMed Web of Science ®Google Scholar
• WeitzJINew oral anticoagulants in developmentThromb Haemost20101031627020062934
   PubMed Web of Science ®Google Scholar
• GarciaDLibbyECrowtherMAThe new oral anticoagulantsBlood20101151152019880491
   PubMed Web of Science ®Google Scholar
• MavrakanasTBounameauxHThe potential role of new oral anti-coagulants in the prevention and treatment of thromboembolismPharmacol Ther20111301465821185864
   PubMed Web of Science ®Google Scholar
• TurpieAGDirect Factor Xa and direct thrombin inhibitors: a clinical trial updateCurr Opin Drug Discov Devel2009124497508
   Google Scholar
• ThanouMHendersonSKydonieusAElsonCN-sulfonato-N,O-carboxymethylchitosan: a novel polymeric absorption enhancer for the oral delivery of macromoleculesJ Control Release2007117217117817184870
   PubMed Web of Science ®Google Scholar
• Bernkop-SchnurchAKastCEGuggiDPermeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systemsJ Control Release20039329510314636716
   PubMed Web of Science ®Google Scholar
• VetterAPereraGLeithnerKKlimaGBernkop-SchnurchADevelopment and in vivo bioavailability study of an oral fondaparinux delivery systemEur J Pharm Sci2010413–448949720705133
   PubMed Web of Science ®Google Scholar
• Khafagyel-SMorishitaMOnukiYTakayamaKCurrent challenges in non-invasive insulin delivery systems: a comparative reviewAdv Drug Deliv Rev200759151521154617881081
   PubMed Web of Science ®Google Scholar
• LamprechtAUbrichNMaincentPOral low molecular weight heparin delivery by microparticles from complex coacervationEur J Pharm Biopharm200767363263817540548
   PubMed Web of Science ®Google Scholar
• JiaoYUbrichNMarchand-ArvierMIn vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbitsCirculation2002105223023511790706
   PubMed Web of Science ®Google Scholar
• HoffartVUbrichNLamprechtAMicroencapsulation of low molecular weight heparin into polymeric particles designed with biodegradable and nonbiodegradable polycationic polymersDrug Deliv20031011712554358
   PubMed Web of Science ®Google Scholar
• PorterCJPoutonCWCuineJFCharmanWNEnhancing intestinal drug solubilisation using lipid-based delivery systemsAdv Drug Deliv Rev200860667369118155801
   PubMed Web of Science ®Google Scholar
• MartinsSSarmentoBFerreiraDCSoutoEBLipid-based colloidal carriers for peptide and protein delivery – liposomes versus lipid nanoparticlesInt J Nanomedicine20072459560718203427
   PubMed Web of Science ®Google Scholar
• ChakrabortySShuklaDMishraBSinghSLipid – an emerging platform for oral delivery of drugs with poor bioavailabilityEur J Pharm Biopharm200973111519505572
   PubMed Web of Science ®Google Scholar
• GotoTMorishitaMNishimuraKNovel mucosal insulin delivery systems based on fusogenic liposomesPharm Res200623238439116382280
   PubMed Web of Science ®Google Scholar
• TakeuchiHMatsuiYYamamotoHKawashimaYMucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to ratsJ Control Release2003862–323524212526820
   PubMed Web of Science ®Google Scholar
• HeurtaultBSaulnierPPechBProustJEBenoitJPA novel phase inversion-based process for the preparation of lipid nanocarriersPharm Res200219687588012134960
   PubMed Web of Science ®Google Scholar
• LacoeuilleFHindreFMoalFIn vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxelInt J Pharm20073441–214314917646066
   PubMed Web of Science ®Google Scholar
• HureauxJLagarceFGagnadouxFLipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxelEur J Pharm Biopharm200973223924619560538
   PubMed Web of Science ®Google Scholar
• PeltierSOgerJMLagarceFCouetWBenoitJPEnhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsulesPharm Res20062361243125016715372
   PubMed Web of Science ®Google Scholar
• RogerELagarceFBenoitJPThe gastrointestinal stability of lipid nanocapsulesInt J Pharm2009379226026519524655
   PubMed Web of Science ®Google Scholar
• CoonJSKnudsonWClodfelterKLuBWeinsteinRSSolutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistanceCancer Res19915138979021988130
   PubMed Web of Science ®Google Scholar
• RogerELagarceFGarcionEBenoitJPLipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosisJ Control Release2009140217418119699246
   PubMed Web of Science ®Google Scholar
• HureauxJLagarceFGagnadouxFToxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in micePharm Res201027342143020054705
   PubMed Web of Science ®Google Scholar
• TurpieAGErikssonBILassenMRBauerKAFondaparinux, the first selective factor Xa inhibitorCurr Opin Hematol200310532733212913785
   PubMed Web of Science ®Google Scholar
• DonatFDuretJPSantoniAThe pharmacokinetics of fondaparinux sodium in healthy volunteersClin Pharmacokinet200241Suppl 21912383039
   PubMed Web of Science ®Google Scholar
• SchieleFFondaparinux and acute coronary syndromes: update on the OASIS 5–6 studiesVasc Health Risk Manag2010617918720407625
   PubMedGoogle Scholar
• SantiRContinoLGattoSLevisAFondaparinux in major orthopedic surgical patientsIntern Emerg Med20105216720195927
   PubMed Web of Science ®Google Scholar
• BauerKAHawkinsDWPetersPCFondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents – the selective factor Xa inhibitorsCardiovasc Drug Rev2002201375212070533
   PubMed Web of Science ®Google Scholar
• RosencherNBellamyLArnaoutLShould new oral antico-agulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery?Arch Cardiovasc Dis2009102432733319427610
   PubMed Web of Science ®Google Scholar
• FrankRDSchabbauerGHolscherTThe synthetic pentasaccharide fondaparinux reduces coagulation, inflammation and neutrophil accumulation in kidney ischemia-reperfusion injuryJ Thromb Haemost20053353154015748244
   PubMed Web of Science ®Google Scholar
• HeurtaultBSaulnierPPechBThe influence of lipid nanocapsule composition on their size distributionEur J Pharm Sci2003181556112554073
   PubMed Web of Science ®Google Scholar
• RawatAMajumderQHAhsanFInhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluationJ Control Release2008128322423218471921
   PubMed Web of Science ®Google Scholar
• KhokhlovVYSelemenevVFKhokhlovaONShcherbininRLHeparin determination by spectrophotometric and photocolorimetric methodsPharm Chem J1999338450451
   Google Scholar
• MotlekarNASrivenugopalKSWachtelMSYouanBBModulation of gastrointestinal permeability of low-molecular-weight heparin by L-arginine: in-vivo and in-vitro evaluationJ Pharm Pharmacol200658559159816640827
   PubMed Web of Science ®Google Scholar
• KlaefflingCPiechottkaGDaemgen-von BrevernGDevelopment and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodiumTher Drug Monit200628337538116778722
   PubMed Web of Science ®Google Scholar
• BianchiniPBergonziniGLParmaBOsimaBRelationship between plasma antifactor Xa activity and the antithrombotic activity of heparins of different molecular massHaemostasis19952562882988586320
   PubMedGoogle Scholar
• StangierJClinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilateClin Pharmacokinet200847528529518399711
   PubMed Web of Science ®Google Scholar
• RogerELagarceFBenoitJPDevelopment and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administrationEur J Pharm Biopharm201179118118821303693
   PubMed Web of Science ®Google Scholar
• HuynhNTPassiraniCSaulnierPBenoitJPLipid nanocapsules: a new platform for nanomedicineInt J Pharm2009379220120919409468
   PubMed Web of Science ®Google Scholar
• HirsjarviSQiaoYRoyereABibetteJBenoitJPLayer-by-layer surface modification of lipid nanocapsulesEur J Pharm Biopharm201076220020720656028
   PubMed Web of Science ®Google Scholar
• MeissnerYUbrichNEl GhazouaniFMaincentPLamprechtALow molecular weight heparin loaded pH-sensitive microparticlesInt J Pharm20073351–214715317150317
   PubMed Web of Science ®Google Scholar
• PeiraECarlottiMETrottaCCavalliRTrottaMPositively charged microemulsions for topical applicationInt J Pharm20083461–211912317618070
   PubMed Web of Science ®Google Scholar
• BaeKHMoonCWLeeYParkTGIntracellular delivery of heparin complexed with chitosan-g-poly(ethylene glycol) for inducing apoptosisPharm Res20092619310018777202
   PubMed Web of Science ®Google Scholar
• MoriSMatsuuraARama PrasadYVTakadaKStudies on the intestinal absorption of low molecular weight heparin using saturated fatty acids and their derivatives as an absorption enhancer in ratsBiol Pharm Bull200427341842114993814
   PubMed Web of Science ®Google Scholar
• MalkovDWangHZDinhSGomez-OrellanaIPathway of oral absorption of heparin with sodium N-[8-(2-hydroxybenzoyl)amino] caprylatePharm Res20021981180118412240944
   PubMed Web of Science ®Google Scholar
• MoazedBHiebertLMMovement of heparins across rat gastric mucosa is dependent on molecular weight and pHPharm Res200926118919518937058
   PubMed Web of Science ®Google Scholar
• Rama PrasadYVMinamimotoTYoshikawaYIn situ intestinal absorption studies on low molecular weight heparin in rats using labrasol as absorption enhancerInt J Pharm20042711–222523215129989
   PubMed Web of Science ®Google Scholar
• Scala-BertolaJRabiskovaMLecompteTBonneauxFMaincentPGranules in the improvement of oral heparin bioavailabilityInt J Pharm20093741–2121619446753
   PubMed Web of Science ®Google Scholar
• MousaSAZhangFAljadaAPharmacokinetics and pharmaco-dynamics of oral heparin solid dosage form in healthy human subjectsJ Clin Pharmacol200747121508152018048572
   PubMed Web of Science ®Google Scholar
• BerkowitzSDMarderVJKosuticGBaughmanRAOral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplastyJ Thromb Haemost2003191914191912941031
   PubMed Web of Science ®Google Scholar
• HoffartVLamprechtAMaincentPLecompteTVigneronCUbrichNOral bioavailability of a low molecular weight heparin using a polymeric delivery systemJ Control Release20061131384216697485
   PubMed Web of Science ®Google Scholar
• RogerELagarceFGarcionEBenoitJPBiopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral deliveryNanomedicine (Lond)20105228730620148639
   PubMed Web of Science ®Google Scholar
• StangierJRathgenKStahleHGansserDRothWThe pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBr J Clin Pharmacol200764329230317506785
   PubMed Web of Science ®Google Scholar